Characterization of human monoclonal autoantibody Fab fragments against oxidized LDL

Molecular Immunology

Volumn 44, Issue 5, 2007, Pages 827-836

  Jeon, Young Eun ^a   Seo, Chang Won ^a   Yu, Eun Sun ^a   Lee, Cheol Joo ^a   Park, Sae Gwang ^b   Jang, Young Ju ^a  

^a Ajou University School of Medicine   (South Korea)

^b Department of Microbiology   (South Korea)

Author keywords

Atherosclerosis; Human anti oxLDL monoclonal autoantibody Fab; Macrophage; oxLDL uptake; Plaque

Indexed keywords

AMINO ACID; ANTIGEN; ARGININE; COMPLEMENTARY DNA; EPITOPE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; LIGAND; MONOCLONAL ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; SCAVENGER;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; ATHEROSCLEROSIS; CELL LINE; CLINICAL ARTICLE; FEMALE; HUMAN; LYMPHOCYTE; MACROPHAGE; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATION; PHAGE DISPLAY; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ATHEROSCLEROSIS; AUTOANTIBODIES; AUTOANTIGENS; CELLS, CULTURED; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; LIPOPROTEINS, LDL; MACROPHAGES, PERITONEAL; MALONDIALDEHYDE; MICE; MICE, INBRED ICR; MOLECULAR SEQUENCE DATA;

EID: 33748773882     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2006.04.005     Document Type: Article

References (49)

1. Andris-Widhopf J., Rader C., Steinberger P., Fuller R., and Barbas III C.F. Methods for the generation of chicken monoclonal antibody fragments by phage display. J. Immunol. Methods 242 (2000) 159-181
2. Barbas III C.F., Burton D.R., Scott J.K., and Silverman G.J. Antibody libraries. In: Kuhlman T., Debruin D., and Barker P. (Eds). Phage Display: A Laboratory Manual. first ed. (2001), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York
3. Barbas III C.F., Crowe Jr. J.E., Cababa D., Jones T.M., Zebedee S.L., Murphy B.R., Chanock R.M., and Burton D.R. Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10164-10168
4. Binder C.J., Horkko S., Dewan A., Chang M.K., Kieu E.P., Goodyear C.S., Shaw P.X., Palinski W., Witztum J.L., and Silverman G.J. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 9 (2003) 736-743
5. Chien N.C., Roberts V.A., Giusti A.M., Scharff M.D., and Getzoff E.D. Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: proposal of a structural mechanism. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 5532-5536
6. Choi K., Lee H.S., and Chung H.K. Production and characterization of monoclonal antibodies to oxidized LDL. Exp. Mol. Med. 30 (1998) 41-45
7. Cochet O., Kenigsberg M., Delumeau I., Duchesne M., Schweighoffer F., Tocque B., and Teillaud J.L. Intracellular expression and functional properties of an anti-p21Ras scFv derived from a rat hybridoma containing specific lambda and irrelevant kappa light chains. Mol. Immunol. 35 (1998) 1097-1110
8. Farrar J., Portolano S., Willcox N., Vincent A., Jacobson L., Newsom-Davis J., Rapoport B., and McLachlan S.M. Diverse Fab specific for acetylcholine receptor epitopes from a myasthenia gravis thymus combinatorial library. Int. Immunol. 9 (1997) 1311-1318
9. Freigang S., Horkko S., Miller E., Witztum J.L., and Palinski W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1972-1982
10. Frostegard J. Autoimmunity, oxidized LDL and cardiovascular disease. Autoimmun. Rev. 1 (2002) 233-237
11. George J., Afek A., Gilburd B., Levkovitz H., Shaish A., Goldberg I., Kopolovic Y., Wick G., Shoenfeld Y., and Harats D. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 138 (1998) 147-152
12. Giles I.P., Haley J., Nagl S., Latchman D.S., Chen P.P., Chukwuocha R.U., Isenberg D.A., and Rahman A. Relative importance of different human aPL derived heavy and light chains in the binding of aPL to cardiolipin. Mol. Immunol. 40 (2003) 49-60
13. Glass C.K., and Witztum J.L. Atherosclerosis. The road ahead. Cell 104 (2001) 503-516
14. Concalves I., Gronholdt M.-L., Söderberg I., Ares M.P.S., Nordestgaard B.G., Bentzon J.F., Fredrikson G.N., and Nilsson J. Humoral immune response against defined oxidised low-density lipoprotein antigens reflects structure and disease activity of carotid plaques. Arterioscler. Thromb. Vasc. Boil. 25 (2005) 1250-1255
15. Hörkkö S., Bird D.A., Miller E., Itabe H., Leitinger N., Subbanagounder G., Berliner J.A., Friedman P., Dennis E.A., Curtiss L.K., Palinski W., and Witztum J.L. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest. 103 (1999) 117-128
16. Jang Y.J., Sanford D., Chung H.Y., Baek S.Y., and Stollar B.D. The structural basis for DNA binding by an anti-DNA autoantibody. Mol. Immunol. 35 (1998) 1207-1217
17. Jang Y.J., and Stollar B.D. Anti-DNA antibodies: aspects of structure and pathogenicity. Cell. Mol. Life Sci. 60 (2003) 309-320
18. Kakutani M., Masaki T., and Sawamura T. A platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 360-364
19. H-CDR3 and specificity for native DNA among autoimmune antibodies. J. Immunol. 157 (1996) 2430-2439
20. Kwon Y.S., Chung J., Shin G.T., Lee S.Y., and Jang Y.J. Variable region genes of human monoclonal autoantibodies to histones H2A and H2B from a systemic lupus erythematosus patient. Mol. Immunol. 42 (2005) 311-317
21. Li A.C., and Glass C.K. The macrophage foam cell as a target for therapeutic intervention. Nat. Med. 8 (2002) 1235-1242
22. Li Z., Schettino E.W., Padlan E.A., Ikematsu H., and Casali P. Structure-function analysis of a lupus anti-DNA autoantibody: central role of the heavy chain complementarity-determining region 3 Arg in binding of double- and single-stranded DNA. Eur. J. Immunol. 30 (2000) 2015-2026
23. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
24. Manderson A.P., Botto M., and Walport M.J. The role of complement in the development of systemic lupus erythematosus. Ann. Rev. Immunol. 22 (2004) 431-456
25. Marion T.N., Bothwell A.L., Briles D.E., and Janeway Jr. C.A. IgG anti-DNA autoantibodies within an individual autoimmune mouse are the products of clonal selection. J. Immunol. 142 (1989) 4269-4274
26. Narvanen O., Erkkila A., and Yla-Herttuala S. Evaluation and characterization of EIA measuring autoantibodies against oxidized LDL. Free Radic. Biol. Med. 31 (2001) 769-777
27. Nuttall S.L., Heaton S., Piper M.K., Martin U., and Gordon C. Cardiovascular risk in systemic lupus erythematosus-evidence of increased oxidative stress and dyslipidaemia. Rheumatology 42 (2003) 758-762
28. Palinski W., Horkko S., Miller E., Steinbrecher U.P., Powell H.C., Curtiss L.K., and Witztum J.L. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J. Clin. Invest. 98 (1996) 800-814
29. Palinski W., Miller E., and Witztum J.L. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl. Acad. Sci. 92 (1995) 821-825
30. Palinski W., Ord V.A., Plump A.S., Breslow J.L., Steinberg D., and Witztum J.L. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler. Thromb. 14 (1994) 605-616
31. Patten P.A., Gray N.S., Yang P.L., Marks C.B., Wedemayer G.J., Boniface J.J., Stevens R.C., and Schultz P.G. The immunological evolution of catalysis. Science 271 (1996) 1086-1091
32. Phillips J.E., and Preston M.R. Inhibition of oxidized LDL aggregation with the calcium channel blocker amlodipine: role of electrostatic interactions. Atherosclerosis 168 (2003) 239-244
33. Radic M.Z., and Weigert M. Genetic and structural evidence for antigen selection of anti-DNA antibodies. Annu. Rev. Immunol. 12 (1994) 487-520
34. Rhew E.Y., and Ramsey-Goldman R. Premature atherosclerotic disease in systemic lupus erythematosus-role of inflammatory mechanisms. Autoimmun. Rev. 5 (2006) 101-105
35. Roben P., Barbas S.M., Sandoval L., Lecerf J.M., Stollar B.D., Solomon A., and Silverman G.J. Repertoire cloning of lupus anti-DNA autoantibodies. J. Clin. Invest. 98 (1996) 2827-2837
36. Roman M.J., Shanker B.A., Davis A., Lockshin M.D., Sammaritano L., Simantov R., Crow M.K., Schwartz J.E., Paget S.A., Devereux R.B., and Salmon J.E. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349 (2003) 2399-2406
37. Rose N., and Afanasyeva M. Autoimmunity: busting the atherosclerotic plaque. Nat. Med. 9 (2003) 641-642
38. Scherer Y., Tenenbaum A., Praprotnik S., Shemesh J., Blank M., Fisman E.Z., Harats D., George J., Levy Y., Peter J.B., Motro M., and Shoenfeld Y. Coronary Artery Disease but Not Coronary Calcification Is Associated with Elevated Levels of Cardiolipin, Beta-2-lycoprotein-I, and Oxidized LDL Antibodies. Cardiology 95 (2001) 20-24
39. Sekiguchi D.R., Eisenberg R.A., and Weigert M. Secondary heavy chain rearrangement: a mechanism for generating anti-double-stranded DNA B cells. J. Exp. Med. 197 (2003) 27-39
40. Shaw P.X., Horkko S., Chang M.K., Curtiss L.K., Palinski W., Silverman G.J., and Witztum J.L. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J. Clin. Invest. 105 (2000) 1731-1740
41. Shaw P.X., Horkko S., Tsimikas S., Chang M.K., Palinski W., Silverman G.J., Chen P.P., and Witztum J.L. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1333-1339
42. Shimada K., Mokuno H., Matsunaga E., Miyazaki T., Sumiyoshi K., Miyauchi K., and Daida H. Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis 174 (2004) 343-347
43. Shlomchik M., Mascelli M., Shan H., Radic M.Z., Pisetsky D., Marshak-Rothstein A., and Weigert M. Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation. J. Exp. Med. 171 (1990) 265-292
44. Sparks D.L., and Phillips M.C. Qantitative measurement of lipoprotein surface charge by agarose gel electrophoresis. J. Lipid Res. 33 (1992) 123-130
45. Steinbrecher U.P. Oxidation of Human Low Density Lipoprotein Results in Derivatization of Lysine Residues of Apolipoprotein B by Lipid Peroxide Decomposition Products. J. Biol. Chem. 262 (1987) 3603-3608
46. Stemme S., Faber B., Holm J., Wiklund O., Witztum J.L., and Hansson G.K. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 3893-3897
47. Strong R.K., Petsko G.A., Sharon J., and Margolies M.N. Three-dimensional structure of murine anti-p-azophenylarsonate Fab 36-71.1: X-ray crystallography, site-directed mutagenesis, and modeling of the complex with hapten. Biochemistry 30 (1991) 3739-3748
48. Wu R., and Lefvert A.K. Autoantibodies against oxidized low density lipoproteins (oxLDL): characterization of antibody isotype, subclass, affinity and effect on the macrophage uptake of oxLDL. Clin. Exp. Immunol. 102 (1995) 174-180
49. Zhou X., Caligiuri G., Hamsten A., Lefvert A.K., and Hansson G.K. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 108-114